Efficacy and safety of belimumab therapy in lupus nephritis: a systematic review and meta-analysis

BACKGROUND: Belimumab is the first biological agent approved for the treatment of systemic lupus erythematosus (SLE), but the efficacy of belimumab for lupus nephritis (LN) is not clear. We conducted this meta-analysis and systematic review to compare the efficacy and safety of belimumab with those...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Han, Chen, Juan, Zhang, Ying, Zhao, Na, Xu, Dongmei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Systematic Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10193908/
https://www.ncbi.nlm.nih.gov/pubmed/37194710
http://dx.doi.org/10.1080/0886022X.2023.2207671

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10193908/
https://www.ncbi.nlm.nih.gov/pubmed/37194710
http://dx.doi.org/10.1080/0886022X.2023.2207671

Ejemplares similares